Last mentioned: Mar 25, 2026
Phase III Milestones
Anticipated data readouts for TCT imaging agents supported by Cu-64 supply.
Supply Chain Integration
Integration of Theragenics' output into Clarity's clinical trial logistics.
Production Ramp-up
Expected commencement of large-scale isotope production for late-stage clinical trials.
Process Integration
Technical teams begin integrating manufacturing protocols and quality control standards.
Agreement Signed
Clarity and Theragenics formalize the large-scale manufacturing supply deal for Cu-64.
Supply Agreement Signed
Clarity and Theragenics formalize large-scale Cu-64 manufacturing partnership.
Clarity Pharmaceuticals has signed a major manufacturing supply agreement with Theragenics to secure large-scale production of copper-64. This partnership bolsters the supply chain for Clarity’s Targeted Copper Theranostics platform as it moves toward late-stage clinical trials.
Clarity Pharmaceuticals has entered into a multi-year manufacturing supply agreement with Theragenics for the production of copper-64 (Cu-64). This partnership secures a reliable, large-scale supply of the isotope to support Clarity's clinical trials and future commercialization of its Targeted Copper Theranostics platform.
Clarity Pharmaceuticals has secured a large-scale manufacturing supply agreement with Theragenics for the production of copper-64. This strategic partnership addresses critical supply chain bottlenecks for radiopharmaceuticals, ensuring a reliable flow of isotopes for Clarity’s diagnostic and therapeutic clinical trials.